Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Labeling DNA Probes03:31

Labeling DNA Probes

DNA probes are fragments of DNA labeled with a reporter tag to enable their detection or purification. The resulting labeled DNA probes can then hybridize to target nucleic acid sequences through complementary base-pairing, and may be used to recover or identify these regions.
Radioisotopes, fluorophores, or small molecule binding partners like biotin or digoxigenin, are the most widely used reporter tags for labeling DNA probes. These labels can be attached to the probe DNA molecule via...
Immunogold Electron Microscopy01:20

Immunogold Electron Microscopy

Immunoelectron microscopy utilizes immunogold labeling of endogenous proteins with specific antibodies to detect and localize these proteins in cells and tissues. The procedure provides insights into the distribution and quantification of protein under different stimulation conditions offering clues about their functions. Conjugating highly electron-dense gold particles with primary or secondary antibodies allow antigen detection on and within cells, with high resolution and specificity.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.

European journal of nuclear medicine and molecular imaging·2020
Same author

Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.

Human vaccines & immunotherapeutics·2017
Same author

Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.

Bioconjugate chemistry·2014

Related Experiment Video

Updated: Jul 14, 2026

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
09:29

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

Novel radiolabeled antibody conjugates.

D M Goldenberg1, R M Sharkey

  • 1Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA. dmg.gscancer@att.net

Oncogene
|May 29, 2007
PubMed
Summary

Radioimmunoconjugates show promise for cancer therapy, but direct antibody-radionuclide linking faces limitations. Pretargeting strategies, like the dock-and-lock method, improve tumor targeting and radiation delivery for better cancer treatment outcomes.

Area of Science:

  • Oncology
  • Radiochemistry
  • Immunotherapy

Background:

  • Radioimmunoconjugates (RICs) are a developing class of cancer therapeutics utilizing radioactive antibodies to target tumors.
  • Directly conjugated antibodies have shown preclinical promise but limited clinical success, except in specific hematological or localized cancers.
  • Conventional radioimmunotherapy faces challenges in specificity and effective radiation dose delivery to tumors.

Purpose of the Study:

  • To review the development of radioimmunoconjugates for cancer therapy.
  • To highlight the potential of pretargeting strategies to overcome limitations of conventional radioimmunotherapy.
  • To focus on the application of bispecific, trimeric constructs using the 'dock-and-lock' antibody engineering method in pretargeting.

Main Methods:

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Experiment Videos

Last Updated: Jul 14, 2026

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies
09:29

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

  • Review of historical development and various approaches in radioimmunoconjugate research.
  • Analysis of preclinical and clinical data for direct conjugation versus pretargeting methods.
  • Examination of the 'dock-and-lock' antibody engineering technique for creating bispecific, trimeric constructs for pretargeting.

Main Results:

  • Directly conjugated antibodies have demonstrated limited clinical efficacy in solid tumors, with success mainly in radiosensitive hematological neoplasms or minimal disease.
  • Pretargeting, a multistep approach separating tumor targeting from radionuclide delivery, shows potential for increased sensitivity, specificity, and higher radiation doses.
  • Initial data suggest that bispecific, trimeric constructs developed via the 'dock-and-lock' method are promising for pretargeting applications.

Conclusions:

  • Pretargeting represents a significant advancement over conventional radioimmunotherapy, offering improved therapeutic potential for cancer treatment.
  • The 'dock-and-lock' method provides a novel antibody engineering approach for developing advanced pretargeting agents.
  • Further development and clinical evaluation of pretargeting strategies, particularly those employing novel antibody constructs, are warranted for effective cancer therapeutics.